Merck, J&J Head To Arbitration Over Remicade Deal
Merck said in a regulatory filing Tuesday that the hearing would take place before a three-judge panel late this month in New York City and is expected to last 12 days. A decision is expected 20 days after the end of the hearing, it said.
Johnson & Johnson requested the arbitration...
To view the full article, register now.